**Table 1. Information on the control plasma samples**

|  |  |  |  |
| --- | --- | --- | --- |
| **Samples (#)** | **Patient’s age, years** | **Gender** | **TNM stage** |
| Colorectal cancer: | | | |
| K193 | 65 | M | T3N0M0 (IIa) |
| K114 | 67 | M | T4N0M0 (IIb) |
| K10 | 65 | M | T3N0M0 (IIa) |
| 13 | 54 | F | T2N0M0 (I) |
| 17 | 51 | M | T2N0M0 (I) |
| 26 | 63 | F | T3N0M0 (IIa) |
| Non-cancer control: |  |  |  |
| 26р | 55 | F | T0N0M0 |
| 12р | 40 | F | T0N0M0 |

F, female; M, male; TNM, cancer staging system by the American Joint Committee on Cancer (AJCC)

**Table 2. Nucleotide sequences of the oligonucleotide DNA probes covalently immobilized on the surface of nanowire chips**

|  |  |  |
| --- | --- | --- |
| **Name of oDNA probe** | **Nucleotide sequence of the oDNA probe** | **Complementary target circRNA** |
| probe\_1 | (NH2)-TTTTTTTTTTAGGACTTCCCCATTG | hsa\_circ\_0031263 [16] |
| probe\_2 | (NH2)-TTTTTTTTTTTTAAAAGCCATTTCC | hsa\_circ\_0072715 [16] |
| probe\_3 | (NH2)-TTTTTTTTTTGTAGCTCTGCACCCA | hsa\_circ\_0136666 [16] |

DNA probe, the DNA fragment complementary to the target biomolecule regions; circRNA, circular RNA; oDNA, oligonucleotide DNA

**Table 3. The used model DNA oligonucleotides with the sequences corresponding to the target regions of the circular RNA and complementary to oDNA probe**

|  |  |  |
| --- | --- | --- |
| **Model oDNA** | **Model oDNA sequence complementary to the oDNA probe** | **CircRNA corresponding to the model oDNA** |
| cs\_1 | CAATGGGGAAGTCCT | hsa\_circ\_0031263 [16] |
| cs\_2 | GGAAATGGCTTTTAA | hsa\_circ\_0072715 [16] |
| cs\_3 | TGGGTGCAGAGCTAC | hsa\_circ\_0136666 [16] |

DNA probe, the DNA fragment complementary to the target biomolecule regions; circRNA, circular RNA; oDNA, short fragment of the DNA molecule (oligonucleotide DNA)